Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $249.56 | 5 | 73.2% |
| Food and Beverage | $91.16 | 5 | 26.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $153.55 | 4 | $0 (2023) |
| Janssen Biotech, Inc. | $99.00 | 1 | $0 (2017) |
| PFIZER INC. | $29.26 | 2 | $0 (2019) |
| Blue Earth Diagnostics Limited | $23.06 | 1 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $21.31 | 1 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $14.54 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21.31 | 1 | E.R. Squibb & Sons, L.L.C. ($21.31) |
| 2023 | $53.56 | 3 | Astellas Pharma US Inc ($53.56) |
| 2020 | $14.54 | 1 | Rigel Pharmaceuticals, Inc. ($14.54) |
| 2019 | $29.26 | 2 | PFIZER INC. ($29.26) |
| 2018 | $23.06 | 1 | Blue Earth Diagnostics Limited ($23.06) |
| 2017 | $198.99 | 2 | Astellas Pharma US Inc ($99.99) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/26/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | In-kind items and services | $21.31 | General |
| Category: Oncology | ||||||
| 11/30/2023 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: Oncology | ||||||
| 08/23/2023 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: Oncology | ||||||
| 07/12/2023 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: Oncology | ||||||
| 11/03/2020 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: Hematology | ||||||
| 03/12/2019 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $14.63 | General |
| Category: ONCOLOGY | ||||||
| 02/14/2019 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $14.63 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2018 | Blue Earth Diagnostics Limited | Axumin (Drug) | Food and Beverage | In-kind items and services | $23.06 | General |
| Category: Diagnostic Imaging | ||||||
| 11/01/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.99 | General |
| 10/10/2017 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Education | In-kind items and services | $99.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 413 | 845 | $186,421 | $43,956 |
| 2022 | 4 | 474 | 1,028 | $199,732 | $55,826 |
| 2021 | 5 | 577 | 1,339 | $253,641 | $76,654 |
| 2020 | 7 | 699 | 1,401 | $261,142 | $70,344 |
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 163 | 358 | $70,968 | $16,066 | 22.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 140 | 301 | $60,126 | $14,342 | 23.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 49 | 90 | $26,176 | $6,585 | 25.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 50 | 85 | $24,784 | $5,935 | 23.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $4,367 | $1,029 | 23.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 275 | 688 | $116,544 | $33,261 | 28.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 85 | 187 | $48,536 | $13,645 | 28.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 53 | 61 | $11,444 | $3,195 | 27.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 27 | 54 | $12,474 | $2,832 | 22.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 16 | 20 | $5,620 | $1,563 | 27.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 18 | 18 | $5,114 | $1,329 | 26.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 365 | 948 | $148,672 | $46,961 | 31.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 116 | 222 | $53,571 | $16,290 | 30.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 42 | 115 | $25,343 | $6,596 | 26.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 42 | 42 | $21,399 | $5,578 | 26.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 12 | 12 | $4,656 | $1,229 | 26.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 364 | 854 | $127,778 | $33,313 | 26.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 134 | 292 | $67,116 | $18,086 | 26.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 50 | 50 | $24,610 | $6,916 | 28.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 43 | 93 | $19,752 | $5,598 | 28.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 55 | 58 | $7,596 | $2,449 | 32.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 33 | 34 | $6,740 | $2,047 | 30.4% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 20 | 20 | $7,550 | $1,936 | 25.6% |
About Dr. Henry Sonneborn, MD
Dr. Henry Sonneborn, MD is a Hematology & Oncology healthcare provider based in Dover, New Hampshire. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376508812.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Henry Sonneborn, MD has received a total of $340.72 in payments from pharmaceutical and medical device companies, with $21.31 received in 2024. These payments were reported across 10 transactions from 6 companies. The most common payment nature is "Education" ($249.56).
As a Medicare-enrolled provider, Sonneborn has provided services to 2,163 Medicare beneficiaries, totaling 4,613 services with total Medicare billing of $246,781. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Dover, NH
- Active Since 04/18/2006
- Last Updated 02/25/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1376508812
Products in Payments
- IMBRUVICA (Drug) $99.00
- Xtandi (Drug) $32.73
- XTANDI (Drug) $29.26
- Axumin (Drug) $23.06
- OPDIVO (Biological) $21.31
- Padcev (Drug) $20.83
- Tavalisse (Drug) $14.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Dover
Amy Bessnow, Md, MD
Hematology & Oncology — Payments: $9,110
Dr. Archana Bhargava, Md, MD
Hematology & Oncology — Payments: $2,577
Gregory Berk, Md, MD
Hematology & Oncology — Payments: $600.00
Prashant Shankar, Md, MD
Hematology & Oncology — Payments: $484.85
Dr. Lamberto Arellano, Md, MD
Hematology & Oncology — Payments: $14.63
Vaishnavi Singh
Hematology & Oncology